Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 11, 2004, Pages 2137-2142

  Brånén, Lena ^a,d   Hovgaard, Lars ^b   Nitulescu, Mihaela ^a   Bengtsson, Eva ^a   Nilsson, Jan ^a   Jovinge, Stefan ^a,c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LUND UNIVERSITY   (Sweden)

^d MAS   (Sweden)

Author keywords

Atherosclerosis; Genetically altered mice; TNF

Indexed keywords

APOLIPOPROTEIN E; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BONE MARROW TRANSPLANTATION; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; INFLAMMATION; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL; DRUG IMPLANTS; FEMALE; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; LIPOPROTEINS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 8344275053     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000143933.20616.1b     Document Type: Article

References (33)

1. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988;57:505-518.
2. Jovinge S, Hamsten A, Tornvall P, Proudler A, Båvenholm P, Ericson CG. Evidence of a role of tumor necrosis factor alpha in disturbances of triglyceride and Metabolism. 1998;47:113-118.
3. Ruuls SR, Sedgewick JD. Unlinking tumor necrosis factor biology from the major histocompatibility complex: lessons from human genetics and animal models. Am J Hum Genet. 1999;65:294-301.
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-126.
5. Rajavashisth TB, Xu XP, Jovinge S, Mejsel S, Xu XO, Chai NN, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation. 1999;99:3103-3109.
6. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann NY Acad Sci. 1995;748:501-507.
7. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem. 1988;263:5797-5803.
8. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334:1717-1725.
9. Browning JL, Dougas I, Ngam-ek A, Bourdon PR, Ehrenfels BN, Miatkowski K, Zafari M, Yampaglia AM, Lawton P, Meier W, et al. Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors. J Immunol. 1995;154:33-46.
10. Mutru O, Laakso M, Isomaki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology. 1989;76:71-77.
11. del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737-2745.
12. Mikuls TR, Moreland LW. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin Pharmacother. 2001;2:75-84.
13. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.
14. Sandborn WJ. Strategies targeting tumor necrosis factor in Crohn's disease. Acta Gastroenterol BeIg, 2001;64:170-172.
15. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
16. Pasparakis M, Alexopoulou L, Episkopou V, Kollias G. Immune and inflammatory response in TNF-α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centetrs, and in the maturation of the humoral immune response. J Exp Med. 1996;184:1397-1411.
17. Brånén L, Pettersson L, Lindholm M, Zaina S. A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified. Histochem J. 2001;33:227-229.
18. Eliaz R, Wallach D, Kost J. Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor. 1996;8:482-487.
19. Talts JF, Brakebusch C, Fassler R. Integrin gene targeting. Methods Mol Biol. 1999;129:153-187.
20. Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol. 2002;168:3088-3098.
21. Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Invest Drugs. 2000;9:497-514.
22. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876-1890.
23. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
24. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
25. Taylor PC. Anti-tumor necrosis factor therapies. Curr Opin Rheumatol. 2001;13:164-169.
26. Murray KM, Dahl SL. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis. Ann Pharmacother. 1997;31:1335-1338.
27. LaDuca JR, Gaspari AA. Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin. 2001;19:617-635.
28. Van Eck M, Herijgers N, Yates J, Pearce NJ, Hoogerbrugge PM, Groot PH, Van Berkel TJ. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:3117-3126.
29. Schreyer SA, Vick CM, LeBoeuf RC. Loss of lymphotoxin-alpha, but not tumor necrosis factor-alpha reduces atherosclerosis in mice. J Biol Chem. 2002;23:23.
30. Canault M, Peiretti F, Mueller C, Kopp F, Morange P, Rihs S, Portugal H, Juhan-Vague I, Nalbone G. Exclusive expression of transmembrane TNF-α in mice reduces the inflammatory response in early lipid lesions of aortic sinus. Atherosclerosis. 2004;172:211-218.
31. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-240.
32. Tangirala RK, Rubin EM, Palinski W. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic. J Lipid Res. 1995;36:2320-2329.
33. Ohshima Y, Yang LP, Avice MN, Kurimoto M, Nakajima T, Sergerie M, Demeure CE, Sarfati M, Delespesse G. Naive human CD4+ T cells are a major source of lymphotoxin alpha. J Immunol. 1999;162:3790-3794.